Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics


The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present invention discloses novel RNA  and RNA/DNA nanoparticles including  multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. These RNA nanoparticles are useful for various nanotechnological applications. This technology has a higher detection sensitivity and higher silencing efficiencies of targeted genes than conventional siRNAs.  This technology has significant therapeutic potential against multiple disease types, including, cancer and viral infections.  Xxenograft mouse models indicated uptake of the nanoparticles, and six different HIV targets were validated with cell cultures.



Potential Commercial Applications: Competitive Advantages:
  • Treatment for cancer and HIV
 
  • Potential for higher sensitivity, higher efficiency, low cytotoxicity, multiple functionality, multiple targets, and controlled activation


Development Stage:
Pre-clinical (in vivo)

Related Invention(s):
E-039-2012
E-156-2014


Inventors:

Bruce Shapiro (NCI)  ➽ more inventions...

Kirill Afonin ()  ➽ more inventions...

Angelica Martins ()  ➽ more inventions...

Mathias Viard ()  ➽ more inventions...


Intellectual Property:
US National Stage Application No. 15/022,530

Publications:
Kirill A. Afonin, et al. "Triggering of RNA Interference with RNA-RNA, RNA-DNA, and DNA- RNA Nanoparticles"  PMID: 25521794

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-765-2013
Updated: Jun 18, 2018